FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

1230118007: Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug)


Status: current, Sufficiently defined by necessary conditions definition status. Date: 30-Jun 2022. Module: SNOMED CT core module

Descriptions:

Id Description Lang Type Status Case? Module
5067244011 Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder en Synonym Active Entire term case insensitive SNOMED CT core module
5067245012 Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) en Fully specified name Active Entire term case insensitive SNOMED CT core module


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Is a Product containing only bacitracin and neomycin and sulfacetamide in cutaneous dose form (medicinal product form) true Inferred relationship Existential restriction modifier
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has manufactured dose form Conventional release cutaneous powder true Inferred relationship Existential restriction modifier
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Plays role Antibacterial therapeutic role true Inferred relationship Existential restriction modifier
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has precise active ingredient Sulfacetamide sodium true Inferred relationship Existential restriction modifier 1
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has basis of strength substance Sulfacetamide sodium true Inferred relationship Existential restriction modifier 1
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has concentration strength numerator unit milligram true Inferred relationship Existential restriction modifier 1
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has concentration strength denominator unit gram true Inferred relationship Existential restriction modifier 1
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has precise active ingredient Bacitracin true Inferred relationship Existential restriction modifier 2
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has basis of strength substance Bacitracin true Inferred relationship Existential restriction modifier 2
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has concentration strength numerator unit Unit true Inferred relationship Existential restriction modifier 2
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has concentration strength denominator unit gram true Inferred relationship Existential restriction modifier 2
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has precise active ingredient Neomycin sulfate true Inferred relationship Existential restriction modifier 3
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has basis of strength substance Neomycin sulfate true Inferred relationship Existential restriction modifier 3
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has concentration strength numerator unit milligram true Inferred relationship Existential restriction modifier 3
Product containing precisely bacitracin 250 unit/1 gram and neomycin sulfate 5 milligram/1 gram and sulfacetamide sodium 60 milligram/1 gram conventional release cutaneous powder (clinical drug) Has concentration strength denominator unit gram true Inferred relationship Existential restriction modifier 3

Inbound Relationships Type Active Source Characteristic Refinability Group

This concept is not in any reference sets

Back to Start